This article is more than 5 years old. Information may no longer be current.
Cervical cancer prevention program prevented cancer death in women with HIV
Click Here to Manage Email Alerts
42nd Annual Meeting of the Society for Gynecologic Oncologists
ORLANDO — A cervical cancer prevention program reduced morbidity and mortality of cervical cancer among women with HIV in Zambia, South Africa, according to a study presented by Groesbeck Parham, MD, of the University of Alabama in Birmingham.
Nurses in Zambia were trained to conduct cervical cancer screenings, with visual inspection with acetic acid, aided by digital cervicography. Women who had visible cervical lesions were offered same-day cryotherapy or were referred for histologic evaluation. Women who had invasive cervical cancer were referred for surgery or radiation.
From 2006 to 2008, 21,010 women were screened, of which 31% had HIV. Among the patients with HIV, 53.6% had visible lesion. Among these, 58.5% were eligible for cryotherapy, and the remaining women were referred for histologic evaluation.
Among the women who underwent histologic screening, 75% underwent therapy. For women who underwent histologic screening, pathology results were available for 65%. Among those with pathology results, benign abnormalities were revealed in 21%, and grade 1 cervical intraepithelial neoplasia was revealed in 30%. Grade 2/3 cervical intraepithelial neoplasia was revealed in 33% of the women, and 16.1% of the women had invasive cervical cancer.
The researchers used a conditional probability model to estimate the prevention of cervical cancer death. They estimated that their program prevented 142 cervical cancer deaths in 6,572 women with HIV, equivalent to one cancer death prevented per 46 women with HIV.
“Concerted efforts for implementing cervical cancer prevention programs integrated with HIV/AIDS care programs are warranted,” Parham said. “Our prevention model can serve as the implementation platform for future low-cost HPV-based screening methods.”
For more information:
- Parham G. #4. Presented at: 42nd Annual Meeting of the Society of Gynecologic Oncologists; March 6-9, 2011; Orlando, Fla.
Disclosure: The researchers report no relevant financial disclosures.
 |
Follow HemOncToday.com on Twitter. |